Condition: Prostatic Neoplasms, Castration-Resistant · Sponsor: Clarity Pharmaceuticals Ltd
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
This description comes directly from the study's public registry record.
Clarity Pharmaceuticals · +61 (0) 2 9209 4037 · clinicaltrials@claritypharmaceuticals.com
Always discuss trial participation with your own doctor first.
| Stanford Cancer Institute | Stanford, California, United States | Recruiting |
| East Jefferson General Hospital | River Ridge, Louisiana, United States | Recruiting |
| BAMF Health | Grand Rapids, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Washington University School of Medicine at Barnes-Jewish Hospital | St Louis, Missouri, United States | Recruiting |
| XCancer | Omaha, Nebraska, United States | Recruiting |
| Weill Cornell Medicine at New York-Presbyterian | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04868604